Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03964220 · ClinicalTrials.gov registry record
Impact of Tiotropium Add-on Therapy in Patients With Asthma
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 7,857
- Enrollment target
NCT03964220: Completed study, sponsored by Boehringer Ingelheim.
NCT03964220 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 7,857 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03964220 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 7,857 participants
- Enrollment target
Study Summary
To evaluate the effectiveness of add on therapy with Tiotropium Respimat® compared to increasing the dose of ICS in patients with a diagnosis of Asthma and on ICS/LABA therapy
Primary Outcome
Exacerbations will be defined as either a hospitalization with a primary diagnosis of asthma, an emergency room (ER) visit with a primary diagnosis of asthma, an asthma exacerbation diagnosis recorded.
Interventions
- DRUG Tiotropium Respimat®
- DRUG Inhaled Corticosteroid/Long-acting beta-agonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,857 participants |
| Start Date | 2019-03-15 |
| Est. Completion | 2019-09-20 |
What the finished NCT03964220 record still lists
NCT03964220 is an observational study that tracks outcomes without assigning an intervention. Its 7,857 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Tiotropium Respimat® is the first listed.
NCT03964220 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03964220 about?
NCT03964220 is a clinical study titled "Impact of Tiotropium Add-on Therapy in Patients With Asthma". To evaluate the effectiveness of add on therapy with Tiotropium Respimat® compared to increasing the dose of ICS in patients with a diagnosis of Asthma and on ICS/LABA therapy
What is the current status of trial NCT03964220?
This trial is currently completed. The enrollment target is 7,857 participants. The study started on 2019-03-15. Estimated completion is 2019-09-20.
What interventions are being tested in trial NCT03964220?
The interventions under investigation include: Tiotropium Respimat® (DRUG), Inhaled Corticosteroid/Long-acting beta-agonist (DRUG).
Who is sponsoring clinical trial NCT03964220?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00539162 · 8,000 participants · NA
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
- NCT00898638 · 8,000 participants
Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
- NCT02240862 · 8,000 participants
The CREST-2 Registry
- NCT03072927 · 8,000 participants
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI